Guest Host: Jen Golbeck

The chief executive of a pharmaceutical company caused a public outcry when he acquired sole U.S. rights to distribute a lifesaving drug and raised the price by more than 5000 percent. But the issue goes well beyond one company and one former hedge fund manager. A number of companies have been quietly cornering the market on older, off-patent drugs–and hiking prices. We speak with a medical historian about the economics of drug pricing, and why “generic” doesn’t guarantee competition.


  • Jeremy Greene MD; Professor of Medicine and the History of Medicine, Johns Hopkins University School of Medicine; Author, “Generic: The Unbranding of Modern Medicine.”

Related Links

Topics + Tags


comments powered by Disqus
Most Recent Shows